Art

J-GLOBAL ID：201302299437224951   Reference number：13A1272067

SYNTHETIC MODELS RELATED TO METHOXALEN-CYP2A6 INTERACTIONS. DIMETHOXYBENZOFURAN DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF CYP2A6

メトキサレンCYP2A6相互作用に関連する合成モデル CYP2A6の強力で選択的な抑制剤としてのジメトキシベンゾフラン誘導体

Author (7)： YAMAGUCHI Yuki (Health Sci. Univ. Hokkaido, Hokkaido, JPN) ,  AKIMOTO Ichie (Health Sci. Univ. Hokkaido, Hokkaido, JPN) ,  MOTEGI Kyoko (Health Sci. Univ. Hokkaido, Hokkaido, JPN) ,  YOSHIMURA Teruki (Health Sci. Univ. Hokkaido, Hokkaido, JPN) ,  WADA Keiji (Health Sci. Univ. Hokkaido, Hokkaido, JPN) ,  NISHIZONO Naozumi (Health Sci. Univ. Hokkaido, Hokkaido, JPN) ,  ODA Kazuaki (Health Sci. Univ. Hokkaido, Hokkaido, JPN)
Material： Heterocycles  (International Journal for Reviews and Communications in Heterocyclic Chemistry)
Volume： 87  Issue： 8  Page： 1727-1739  Publication year： Aug. 01, 2013 
JST Material Number： S0966A  ISSN： 0385-5414  CODEN： HTCYAM  Document type： Article
Article type： 短報  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： toxicity test ,  concentration (ratio) ,  *oxygen heterocyclic compound ,  *polynuclear aromatic compound ,  action and effect ,  suppression and control ,  lead compound ,  countermeasure ,  drug ,  chemical synthesis ,  molecular structure ,  interaction ,  nitrogen heterocyclic compound ,  tobacco alkaloid ,  lactone ,  phenol ether ,  50% inhibitory concentration ,  Xenobiotic ,  *Benzofurans
Semi thesaurus term： Smoking countermeasure ,  medical agent ,  inhibitory effect ,  *Benzofurans

JST classification (1)： Oxygen heterocycles in general  (CF07020K)

Substance index (10)： Nicotine ,  Methoxsalen ,  3,4-Dimethoxybenzofuran ,  3,5-Dimethoxybenzofuran ,  3,6-Dimethoxybenzofuran ,  3,7-Dimethoxybenzofuran ,  4,5-Dimethoxybenzofuran ,  4,6-Dimethoxybenzofuran ,  4,7-Dimethoxybenzofuran ,  5,7-Dimethoxybenzofuran

Reference (24)：

• 1. N. L. Benowitz, P. Jacob, I. Fong, and S. Gupta, J. Parmacol. Exp. Ther., 1994, 268, 296.
• 2. T. Shimada, H. Yamazaki, M. Mimura, Y. Inoue, and F. P. Guengerichi, J. Pharmacol. Exp., Ther., 1994,. 270, 414; S. Rendic and F. J. Di Carlo, Drug Metab. Rev., 1997, 29, 413.
• 3. T. Kamataki, M. Fujieda, K. Kiyotani, S. Iwao, and H. Kunitoh, Biochem. Biophys. Res. Commun., 2005, 338, 306; H. Takeuchi, K. Saoo, M. Yokohira, M. Ikeda, H. Maeta, M. Miyazaki, H. Yamazaki, T. Kamataki, and K. Imaida, Cancer Res., 2003, 22, 7581.
• 4. S. J. London, J. R. Idle, A. K. Daly, and G. A. Coetzee, Lancet, 1999, 353, 898.
• 5. T. T. Denton, X. Zhang, and J. R. Cashman, J. Med. Chem., 2005, 48, 224.

Terms in the title (6)： メトキサレン ,  CYP2A6 ,  相互作用 ,  モデル ,  抑制剤 ,  誘導体